搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Gloeobacter violaceus 30S ribosomal protein S10 (rpsJ) CSB-YP742275GCI
CSB-EP742275GCI
CSB-BP742275GCI
CSB-MP742275GCI
CSB-EP742275GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 50S ribosomal protein L16 (rplP) CSB-YP742276GCI
CSB-EP742276GCI
CSB-BP742276GCI
CSB-MP742276GCI
CSB-EP742276GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 30S ribosomal protein S5 (rpsE) CSB-YP742277GCI
CSB-EP742277GCI
CSB-BP742277GCI
CSB-MP742277GCI
CSB-EP742277GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus ATP-dependent Clp protease proteolytic subunit 1 (clpP1) CSB-YP742278GCI
CSB-EP742278GCI
CSB-BP742278GCI
CSB-MP742278GCI
CSB-EP742278GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 3-oxoacyl-[acyl-carrier-protein] synthase 3 (fabH) CSB-YP742279GCI
CSB-EP742279GCI
CSB-BP742279GCI
CSB-MP742279GCI
CSB-EP742279GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Methylenetetrahydrofolate--tRNA- (uracil-5-)-methyltransferase TrmFO (trmFO) CSB-YP742280GCI
CSB-EP742280GCI
CSB-BP742280GCI
CSB-MP742280GCI
CSB-EP742280GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 30S ribosomal protein S4 (rpsD) CSB-YP742281GCI
CSB-EP742281GCI
CSB-BP742281GCI
CSB-MP742281GCI
CSB-EP742281GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Photosystem I P700 chlorophyll a apoprotein A2 (psaB), partial CSB-YP742282GCI
CSB-EP742282GCI
CSB-BP742282GCI
CSB-MP742282GCI
CSB-EP742282GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Undecaprenyl-diphosphatase (uppP), partial CSB-YP742283GCI
CSB-EP742283GCI
CSB-BP742283GCI
CSB-MP742283GCI
CSB-EP742283GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Fructose-1,6-bisphosphatase class 1 (fbp) CSB-YP742284GCI
CSB-EP742284GCI
CSB-BP742284GCI
CSB-MP742284GCI
CSB-EP742284GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 50S ribosomal protein L35 (rpmI) CSB-YP742285GCI
CSB-EP742285GCI
CSB-BP742285GCI
CSB-MP742285GCI
CSB-EP742285GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Shikimate kinase (aroK) CSB-YP742286GCI
CSB-EP742286GCI
CSB-BP742286GCI
CSB-MP742286GCI
CSB-EP742286GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus GMP synthase [glutamine-hydrolyzing] (guaA), partial CSB-YP742287GCI
CSB-EP742287GCI
CSB-BP742287GCI
CSB-MP742287GCI
CSB-EP742287GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Histidine--tRNA ligase (hisS) CSB-YP742288GCI
CSB-EP742288GCI
CSB-BP742288GCI
CSB-MP742288GCI
CSB-EP742288GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Putative 3-methyladenine DNA glycosylase (gll2491) CSB-YP742289GCI
CSB-EP742289GCI
CSB-BP742289GCI
CSB-MP742289GCI
CSB-EP742289GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit H 2 (ndhH2) CSB-YP742290GCI
CSB-EP742290GCI
CSB-BP742290GCI
CSB-MP742290GCI
CSB-EP742290GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Cytochrome c-550 2 (psbV2) CSB-YP742291GCI
CSB-EP742291GCI
CSB-BP742291GCI
CSB-MP742291GCI
CSB-EP742291GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 2-isopropylmalate synthase (leuA), partial CSB-YP742292GCI
CSB-EP742292GCI
CSB-BP742292GCI
CSB-MP742292GCI
CSB-EP742292GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Ribosomal protein L11 methyltransferase (prmA) CSB-YP742293GCI
CSB-EP742293GCI
CSB-BP742293GCI
CSB-MP742293GCI
CSB-EP742293GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus UDP-3-O-acylglucosamine N-acyltransferase 2 (lpxD2) CSB-YP742294GCI
CSB-EP742294GCI
CSB-BP742294GCI
CSB-MP742294GCI
CSB-EP742294GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>